The Hemodynamic Response to Prolonged Dobutamine Infusion

Hadassah Medical Organization100 enrolled

Overview

A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is thought to play a major role in the pathogenesis of diseases such as congestive heart failure. However, currently, there is no in vivo model that will enable us to measure desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo. Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1 adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic responses to dobutamine over time.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

100

Conditions

Healthy Heart Failure

Interventions

3 hours intravenous dobutamineDRUG

Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * healthy subjects Exclusion Criteria: * consumption of any medications during the 2 weeks prior to the study * history of chest pain or tachycardia

Locations (1)

Hadassah University Hospital

Jerusalem, Israel

RECRUITING

Outcomes

Primary Outcomes

Heart rate

Time frame: 3 hours

Secondary Outcomes

Systolic blood pressure

Time frame: 3 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.